ArticlePloS one2025
Drug target affinity prediction based on multi-scale gated power graph and multi-head linear attention mechanism.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For the purpose of developing new drugs and repositioning existing ones, accurate drug-target affinity (DTA) prediction is essential. While graph neural networks are frequently utilized for DTA prediction, it is difficult for existing single-scale graph neural networks to access the global structure of compounds. We propose a novel DTA prediction model in this study, MAPGraphDTA, which uses an approach based on a multi-head linear attention mechanism that aggregates global features based on the attention weights and a multi-scale gated power graph that captures multi-hop connectivity relationships of graph nodes. In order to accurately extract drug target features, we provide a gated skip-connection approach in multiscale graph neural networks, which is used to fuse multiscale features to produce a rich representation of feature information. We experimented on the Davis, Kiba, Metz, and DTC datasets, and we evaluated the proposed method against other relevant models. Based on all evaluation metrics, MAPGraphDTA outperforms the other models, according to the results of the experiment. We also performed cold-start experiments on the Davis dataset, which showed that our model has good prediction ability for unseen drugs, unseen proteins, and cases where neither drugs nor proteins has been seen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.